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Abstract
Background: Plasma cell mastitis is distinct from the common form of mastitis and clinically resembles breast
carcinoma. The lesion occurs in non-lactating young women, and the incidence rate is rising. Surgical resection is
the main treatment, but cannot prevent recurrence of the disease. Disfigurement or removal of breast after the
operations can cause marked physical and psychological distress. The etiology of plasma cell mastitis is unclear up
till now. It is therefore necessary to investigate further the underlying immunological changes of the disease.
Methods: The lesions of plasma cell mastitis removed from patients through aseptic operation were mixed with
normal saline into homogenate tube machine (homogenate tubes were disinfected and sterilized prior to
treatment). The mixture was homogenized at medium speed and grinded in ultrasonic cell disruptor. The
homogenate obtained was made into oil emulsion with Freund’s adjuvant. Thirty female BALB/c mice (6 weeks
after sexual maturity) were divided into five groups A-E: group A was blank control; group B was normal saline
control; group C was inoculated with 0.02 ml water-in-oil emulsion; group D was inoculated with 0.04 ml water-in-
oil emulsion; group E was complete Freund’s adjuvant control.
Results: Pathology results showed that mouse mammary gland acinar cells remained integral without any
abnormal changes observed in control groups A and B. Experimental groups C and D showed dilation of mouse
mammary ductal tissue with a large number of epithelial cells and debris in the lumen, and fibrosis around ducts
accompanied by large duct cells, neutrophils, lymphocytes, and especially plasma cell infiltration. Pathological
changes were observed in 3 (50%) mice and 5 (83.3%) mice in group C and D respectively. In group E, neutrophil
infiltration in mammary gland was observed in 5 mice, but neither infiltration of plasma cells nor other abnormal
pathological changes were observed.
Conclusions: The lesions of patient with plasma cell mastitis could make the female BALB/c mice experience the
similar clinical and pathological manifestation. High-dose group can successfully establish a mouse model of
plasma cell mastitis.
Background
Plasma cell mastitis (PCM), also known as granuloma-
tous mastitis or nonpuerperal mastitis, was first proposed
by Cheatle and Cutler, in 1931[1]. It was a nonbacterial
inflammatory breast disease frequently occurred among
young and middle-aged women at non-pregnancy or
non-lactation stages [2,3]. According to the current
report, the incidence rate of PCM increased gradually,
and extended to pubertal or menopausal women [4-7].
However, little is known about its mechanism as its onset
is occult, but several studies have shown that recurrence
of PCM was commonly observed [8-10]. Surgical excision
is the major treatment of the disease [2,10,11] and wide
local excision was commonly performed as limited surgi-
cal excision might lead to higher rate of recurrence [10].
However, the operation could not prevent the recurrence
of the disease as a discrete mass [12,13] even though the
mammary gland was removed, thus women might experi-
ence mental and physical distress.
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The inflammatory disease clinically mimics breast can-
cer [14,15] and some cases were misguided as breast
cancer [16,17]. Histologically, the disease is presented
with duct widening characterized by periductal inflam-
mation and fibrosis. Some characteristic calcification can
be seen by mammography. Microscopically, granuloma
formation, Langhan’s giant cell, plasma cell, histiocyte,
lymphocyte, and caseous necrosis were observed [18,19].
However, a prospective follow-up study of 270 patients
with nonpuerperal breast inflammation has demon-
strated an increased risk of breast cancer in women
with nonpuerperal mastitis [20]. The correlation
between the inflammatory disease and breast cancer has
not yet been established.
In this study, a PCM mouse model was established by
inoculation of aseptic homogenate of human PCM
pathological tissues and complete Freund’s adjuvant




Agents and equipments applied in this study included
complete Freund’s adjuvant (Sigma-Aldrich Co., Ltd., U.S.
A), low temperature refrigerator (Qingdao Haier Co., Ltd,
China), electronic balance, ultrasonic cell disruptor, tissue
homogenizer and histotome.
Homogenate
Fresh and noninfected PCM pathological tissues were
excised under aseptic conditions. Pathological tissues
(0.1g) mixed with physiological saline at a ratio of 1:3 was
added to the sterilized homogenate pipe. The samples
were homogenated for 5 minutes at intermediate speed.
Ice cubes were placed into the shattering slot of the
machine to guarantee that the shattering samples were
processed at 3 to 4°C. The product was treated with ultra-
sonic cell disruptor (power: 120 W, intermittent time: 10
seconds, working time: 3 seconds, breaking the number of:
60, total duration: 5 minutes). Then the samples were
stored in specimen bottles. For the preparation of water-
in-oil emulsion, samples and CFA were mixed with equal
volume at 0-4°C followed by repeated mixing with syringe
for 20 minutes. The water-in-oil emulsion was stored for
further experiments.
Animals
Thirty sexually mature female BALB/c mice aged 6 weeks
were randomly divided into 5 groups: group A (n = 6,
control ), group B (n = 6, 0.02 ml physiological saline was
injected via the 3rd and 4th pairs of lacteral glands),
group C (n = 6, 0.02 ml water-in-oil emulsion was
injected via the 3rd and 4th pairs of lacteral glands),
group D (n = 6, 0.04 ml water-in-oil emulsion was
injected via the 3rd and 4th pairs of lacteral glands) and
group E (n = 6, 0.02 ml CFA was injected via the 3rd and
4th pairs of lacteral glands). Group A, B and E were
regarded as blank control group, negative control group
and positive control group respectively. Group C and D
were regarded as experimental group. Animals were
sacrificed 1 week after inoculation. Pathological changes
of PCM were detected by hematoxylin & eosin staining.
Positive results were designated in animals with PCM
pathological changes, otherwise negative.
Embedding
Mice purchased from Beijing Vitalriver Co., Ltd. were
housed in the animal breeding room for 1 week. For the
anesthesia, 0.3% chloral hydrate solution was injected via
intraperitoneal injection. Ethanol (75%) was used for the
skin disinfection. Abdominal body hairs of anesthetized
mice were removed at the 3rd and 4th pairs of lacteral
glands. For the embedding, water-in-oil emulsion, sodium
chloride physiological solution and CFA solution were
administrated via subcutaneous injection at the 3rd and
4th pairs of lacteral glands of group C, D and E mice
respectively.
Mammary tissue collection
Animals were sacrificed 1 week after embedding to collect
the tissues from the 3rd and 4th pairs of lacteral glands.
After physiological saline rinsing, the tissues went through
formalin (10%) fixation for 24 hours to prepare for the
paraffin embedding tissues. Then deparaffinage and wash-
ing was performed. The sections were stained with routine
hematoxylin & eosin staining.
Assessments and statistics
The diagnosis of PCM was mainly based on the pathologic
diagnosis of specific tissues including plasmocytes clus-
tered in the peripheral tissues of mammary duct and
lobules of mammary gland combined with infiltration of
neutrophils and lymphocytes. Under the microscope of
high power fields (HPF), negative and positive pathological
changes of PCM were defined as less than 50 inflamma-
tory cells per HPF and 50 or more inflammatory cells per
HPF respectively. Parameters were compared using SPSS
18.0 software. Fisher’s exact test or chi-square test was
used to compare the number of positive pathological find-
ings of PCM between groups. P < 0.05 was considered as
statistically significant.
Results
Histological comparison between experimental group and
control group
Infiltration of plasmocytes, neutrophils and lymphocytes
were detected in the peripheral tissues of lobules of
mammary gland and mammary duct in the experimental
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groups C and D, but not in control groups A, B and E
(Figure 1). It was similar to histopathological presenta-
tion in human plasma cell mastitis (Figure 2). Necrosis
was detected in tissues with severe inflammation. No
infiltration of plasmocytes, neutrophils and lymphocytes
was detected in the control groups. In CFA group, only
slight infiltration of neutrophils and lymphocytes were
observed, but infiltration of plasmocytes was not
observed.
Pathological comparison between experimental group
and control group
In experimental group C and D, swelling and nodules were
detected in lacteal gland 1 day and 3 days after injection of
water-in-oil emulsion respectively. Pathological samples
were taken 1 week after the injection, and abscessation was
detected in the lesion regions. Swelling and nodules were
not observed in Group A and B. In Group E, a small por-
tion of skin bump, where CFA was not absorbed, existed 1
day after CFA injection but no significant rush node swel-
ling was observed. The bump still existed 3 days later with-
out significant changes. No abscessation was noted at the
lesion regions 1 week after the injection. In our study, con-
trol groups A, B and E did not show any pathological
change of PCM as indicated from sections of tissue with
less than 50 inflammatory cells per HPF by microscopic
examination. In experimental groups, more than 50% of
the mice presented with pathological change of PCM. Sig-
nificant difference in PCM pathological changes was
detected between all groups (P = 0.001) (Table 1). A higher
percentage of PCM pathological change was observed in
experimental group than control group with a statistical
significance (P < 0.0001). Within the experimental group,
no difference was detected between group C and group D
(P > 0.05) (Table 2), albeit more mice presented with posi-
tive pathologic changes of PCM in group D than group C.
Figure 1 Histopathological presentation in mouse breast
tissues (A) Control group: No significant plasmocyte infiltration was
observed. (B) Experimental group: Infiltration of plasmocytes,
neutrophils and lymphocytes was detected.
Figure 2 Histopathological presentation in human plasma cell
mastitis
Table 1 Comparison of positive pathological changes of
plasma cell mastitis in different groups
Group Results P
Positive Negative
A 0 (0.0%) 6 (100.0%) 0.001*
B 0 (0.0%) 6 (100.0%)
C 3 (50.0%) 3 (50.0%)
D 5 (83.3%) 1 (16.7%)
E 0 (0.0%) 6 (100.0%)
Group A: blank control; Group B: normal saline control; Group C: inoculated
with 0.02 ml homogenate; Group D: inoculated with 0.04 ml homogenate;
Group E: complete Freund’s adjuvant control.
*Statistically significant by Pearson Chi-Square test
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Discussion
PCM is a rare breast disease that mimics breast cancer and
the etiology remains unclear. It is therefore clinically sig-
nificant to differentiate the inflammatory disease from
malignant disease. Basically, the disease could be categor-
ized into infectious and non-infectious ones which respec-
tively presented as tuberculous mastitis and idiopathic
granulomatous mastitis with distinguishable histological
features [4]. However, the immunological mechanism of
PCM and its associated pathological change were still
unknown. A variety of different terms including granulo-
matous mastitis, mammary duct ectasia or nonlactational
mastitis created unconformity of the designation systems.
Previous studies showed anaerobic infection was the
major cause of PCM, which might result in tumorigenesis
in the infected area [21,22], but the casual relationship
between mastitis and breast cancer was not fully sup-
ported and widely accepted [23]. Currently, PCM was
reported to be associated with nonbacterial infection [24].
Our data indicated that most of the PCM patients showed
a history of inverted nipples, which might lead to stenosis
and obstruction of mammary duct, as well as deposition of
secretions such as breast milk in the mammary duct. We
speculated that long-term deposition of breast milk in
mammary duct could stimulate autoimmune response, fol-
lowed by pathological changes in different parts of the
mammary gland [3].
Surgery was still the preferred treatment of PCM to the
antibiotic treatment which was not efficient. However,
complete remission was not guaranteed after surgery. To
date, bacterial mastitis mouse models were mainly induced
by injection of bacterial liquid via lacteal gland [25] and in
a retrospective review of 26 clinical cases of granuloma-
tous mastitis, idiopathic cases were not associated with
specific micro-organism with negative special stains and
cultures for micro-organisms [26]. In this study, a PCM
mouse model was induced by active ingredient of the
PCM tissues. The possibility of bacteria induced PCM was
eliminated by sterile processing from sample collection to
inoculation and ultrasonic cell disruptor processing after
homogenization. Moreover, CFA was used to promote the
formation of PCM due to the fact that CFA could function
as antigen reservoir and stimulate local inflammation and
granulomatous reaction as well as the proliferation and
differentiation of lymphocytes [27]. The use of CFA in this
study could preclude the possibility of positive pathologi-
cal changes of PCM resulted from enhancement of immu-
nological responses to antigens.
PCM mouse models were established in group C and
group D. Infiltration of plasmocytes, neutrophils and lym-
phocytes was detected in peripheral breast tissues, which
was consistent with the diagnostic standard of PCM. No
statistical difference of PCM pathological changes was
observed between groups. Also, manifestation of PCM was
not observed in group A and B, demonstrating that phy-
siological saline did not have any effect on the develop-
ment of PCM. Infiltration of neutrophils and lymphocytes
was detected in group E, indicating that CFA was not effi-
cient in the induction of PCM even though it functioned
in promoting inflammation. We therefore confirmed that
certain ingredients of pathological tissues from PCM
patients could induce the development of PCM in mouse
models. The first PCM mouse model presented in this
study will provide a platform for the investigation of the
etiology, pathological mechanism and the potential drug
selection for the PCM.
Conclusions
The PCM lesion from patients could induce the develop-
ment of PCM in female BALB/c mice with similar clinical
and pathological manifestation and higher dose of PCM
homogenate succesfully developed PCM in all mice. The
mouse models could be futher investigated to explore the
etiology, disease mechanism as well as potential drug ther-
apy while at the moment traumatic surgery is still the
major treatment for patients with PCM.
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Table 2 Comparison of positive pathological changes of
plasma cell mastitis in Group C and Group D
Group Results P
Positive Negative
C 3 (50.0%) 3 (50.0%) 0.545
D 5 (83.3%) 1 (16.7%)
Group C: inoculated with 0.02 ml homogenate; Group D: inoculated with 0.04
ml homogenate. Fisher’s exact test did not show statistical significance
between groups.
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